Anti-CD47 Therapy
Atherosclerosis / Prevention of Major Adverse Cardiovascular Events (MACE)
Pre-clinicalActive
Key Facts
Indication
Atherosclerosis / Prevention of Major Adverse Cardiovascular Events (MACE)
Phase
Pre-clinical
Status
Active
Company
About Bitterroot Bio
Bitterroot Bio is an early-stage biotech focused on translating immuno-oncology principles to treat cardiovascular disease (CVD), specifically atherosclerosis. The company's core hypothesis is that blocking the 'don't eat me' signal CD47 on harmful cells within arterial plaques will enhance macrophage clearance and halt disease progression. With a world-class scientific founding team and backing from top-tier life science investors, Bitterroot aims to develop first-in-class cardio-immunotherapies. The company is currently in the preclinical/early clinical development stage, positioning itself at the forefront of a potentially transformative new therapeutic paradigm.
View full company profile